Brief: PharmaCyte Announces Tests Results For Pancreatic Cancer Clinical Trial Product Candidate
19/04/2022 14:13
April 19 (Reuters) - PharmaCyte Biotech Inc PMCB.O :
* PHARMACYTE BIOTECH ANNOUNCES MORE POSITIVE TESTS RESULTS
FOR ITS
PANCREATIC CANCER CLINICAL TRIAL PRODUCT CANDIDATE TO SATISFY
FDA REQUIREMENTS
* PHARMACYTE BIOTECH INC - EMPTY CAPSULE MATERIAL THAT
COMPRISES
ITS PANCREATIC CANCER CLINICAL TRIAL PRODUCT CANDIDATE DOES NOT
CAUSE SYSTEMIC TOXICITY
Source text for Eikon: ID:nBw2QW7tta
Further company coverage: PMCB.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Pharmacyte Biotech
See all newsBrief: Pharmacyte Biotech Inc - Increases Stake In Tnf Pharmaceuticals By $3 Million
Brief: PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease
Brief: Pharmacyte Biotech Acquires $5 Million Stake In Emerging Women’S Health Innovator Femasys
Brief: Femasys Inc. Secures Additional Financing With Strategic Investment From Investors Led By Pharmacyte Biotech
Brief: Pharmacyte Biotech Announces Final Results Of Tender Offer